EAElena Avgoustou

Elena Avgoustou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena Avgoustou has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment

    by Elena Avgoustou, Ilektra Tzivaki, Garyfalia Diamantopoulou, Tatiana Zachariadou, Despoina Avramidou, Vasileios Dalopoulos, Alexandros Skourtis

    Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.


  • Open Access

    Incidental detection of hereditary bisalbuminemia in a patient with positive DAT coombs: A case-based review

    by Elena Avgoustou, Dimitris Kounatidis, Natalia G. Vallianou, Irene Karampela, Theodora Stratigou, Maria Dalamaga


  • Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review

    by Dimitris C. Kounatidis, Vasileios Papadimitropoulos, Konstantinos Avramidis, Evgenia Plenga, Ioanna Tsiara, Elena Avgoustou, Natalia Vallianou, Dimitrios Vassilopoulos

    Pneumocystis jirovecii pneumonia (PJP) is a potentially fatal type of pneumonitis, which may have devastating consequences. Typically, it occurs in immunocompromised patients, with the natural history varying depending on the presence or not of HIV infection. Staining and polymerase chain reaction (PCR) testing in induced sputum or bronchoalveolar lavage (BAL) is the cornerstone of the diagnosis, while trimethoprim-sulfamethoxazole is the treatment of choice. The etiological association of biologic agents with the occurrence of PJP is not entirely clear. Adalimumab is a fully human monoclonal anti-TNF-alpha antibody, which has been introduced relatively recently in the treatment of autoimmune inflammatory diseases, such as rheumatoid arthritis. In contrast to other biologic agents, such as Alemtuzumab or Infliximab, there are a small number of reports that support the drug's ability to trigger the occurrence of PJP. Hereby, we present a 53-year-old female patient with a medical history of rheumatoid arthritis on Adalimumab therapy, who developed PJP and we will discuss the main characteristics of PJP and the possible contribution of biologics to the occurrence of the infection.